Skip to main content
Veterinary Medicines

Aftovaxpur DOE (30) O1 Manisa + O1 BFS + A24 Cruzeiro

Authorised
  • Foot-and-mouth disease virus, serotype O, strain O1 Manisa, Inactivated
  • Foot-and-mouth disease virus, serotype O, strain O1 BFS, Inactivated
  • Foot-and-mouth disease virus, serotype A, strain A24 Cruzeiro, Inactivated

Identifikacija zdravila

Ime zdravila:
Aftovaxpur DOE (30) O1 Manisa + O1 BFS + A24 Cruzeiro
Učinkovina:
Pot uporabe:
  • intramuskularna uporaba
  • Subkutana uporaba

Podatki o zdravilu

Učinkovina / Jakost:
  • Na voljo samo v English
    Presentation_strength:≥ 6 PD50 Reference:Hse Index:0
  • Na voljo samo v English
    Presentation_strength:≥ 6 PD50 Index:11
  • Na voljo samo v English
    Presentation_strength:≥ 6 PD50 Index:12
Farmacevtska oblika:
  • Emulzija za injiciranje
Withdrawal period by route of administration:
  • Intramuscular use
    • govedo
      • Not applicable
        0
        day
    • Sheep
      • Not applicable
        0
        day
    • Pig
      • Not applicable
        0
        day
  • Subcutaneous use
    • govedo
      • Not applicable
        0
        day
    • Sheep
      • Not applicable
        0
        day
    • Pig
      • Not applicable
        0
        day
Anatomsko-terapevtsko-kemična veterinarska oznaka (ATCvet):
  • QI02AA04
Status dovoljenja:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Opis ovojnine:

Dodatne informacije

Entitlement type:
Imetnik dovoljenja za promet z zdravilom:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Proizvodna mesta, odgovorna za sproščanje serij:
  • Boehringer Ingelheim Animal Health France
Pristojni organ:
  • European Commission
Številka dovoljenja :
Ta podatek za to zdravilo ni na voljo.
Datum spremembe statusa dovoljenja:

Dokumenti

Combined File of all Documents

slovenščina (PDF)
Objavljeno na: 19/03/2024
Prenesi
Bulgarian (PDF)
Objavljeno na: 19/03/2024
Croatian (PDF)
Objavljeno na: 19/03/2024
Czech (PDF)
Objavljeno na: 19/03/2024
Danish (PDF)
Objavljeno na: 19/03/2024
Dutch (PDF)
Objavljeno na: 19/03/2024
English (PDF)
Objavljeno na: 19/03/2024
Estonian (PDF)
Objavljeno na: 19/03/2024
Finnish (PDF)
Objavljeno na: 19/03/2024
French (PDF)
Objavljeno na: 19/03/2024
German (PDF)
Objavljeno na: 19/03/2024
Greek (PDF)
Objavljeno na: 19/03/2024
Hungarian (PDF)
Objavljeno na: 19/03/2024
Icelandic (PDF)
Objavljeno na: 19/03/2024
Italian (PDF)
Objavljeno na: 19/03/2024
Latvian (PDF)
Objavljeno na: 19/03/2024
Lithuanian (PDF)
Objavljeno na: 19/03/2024
Maltese (PDF)
Objavljeno na: 19/03/2024
Norwegian (PDF)
Objavljeno na: 19/03/2024
Polish (PDF)
Objavljeno na: 19/03/2024
Portuguese (PDF)
Objavljeno na: 19/03/2024
Romanian (PDF)
Objavljeno na: 19/03/2024
Slovak (PDF)
Objavljeno na: 19/03/2024
Spanish (PDF)
Objavljeno na: 19/03/2024
Swedish (PDF)
Objavljeno na: 19/03/2024

ema-puar-aftovaxpur-v-2292-var-ii-0009-en.pdf

English (PDF)
Objavljeno na: 6/02/2023
Prenesi

ema-puar-aftovaxpur-v-2292-par-en.pdf

English (PDF)
Objavljeno na: 6/02/2023
Prenesi

ema-puar-aftovaxpur-v-2292-var-ii-0001-en.pdf

English (PDF)
Objavljeno na: 6/02/2023
Prenesi
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."